Aevi Genomic Medicine Inc (NASDAQ:GNMX) – Investment analysts at Zacks Investment Research issued their Q1 2019 earnings per share estimates for Aevi Genomic Medicine in a research note issued on Wednesday, April 10th. Zacks Investment Research analyst B. Marckx anticipates that the biotechnology company will earn ($0.10) per share for the quarter. Zacks Investment Research also issued estimates for Aevi Genomic Medicine’s Q2 2019 earnings at ($0.10) EPS, Q3 2019 earnings at ($0.05) EPS, Q4 2019 earnings at ($0.05) EPS and FY2021 earnings at ($0.18) EPS.

Several other research firms have also commented on GNMX. ValuEngine lowered Aevi Genomic Medicine from a “hold” rating to a “sell” rating in a research report on Thursday, December 20th. JMP Securities lowered Aevi Genomic Medicine from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 3rd.

Shares of NASDAQ GNMX opened at $0.21 on Monday. The company has a market capitalization of $12.95 million, a P/E ratio of -0.25 and a beta of 0.32. Aevi Genomic Medicine has a 52 week low of $0.17 and a 52 week high of $1.80.

A hedge fund recently raised its stake in Aevi Genomic Medicine stock. Virtu Financial LLC grew its stake in Aevi Genomic Medicine Inc (NASDAQ:GNMX) by 675.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 278,958 shares of the biotechnology company’s stock after purchasing an additional 242,994 shares during the period. Virtu Financial LLC owned about 0.43% of Aevi Genomic Medicine worth $55,000 at the end of the most recent quarter. 19.18% of the stock is owned by institutional investors and hedge funds.

About Aevi Genomic Medicine

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.

See Also: Derivative

Earnings History and Estimates for Aevi Genomic Medicine (NASDAQ:GNMX)

Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with's FREE daily email newsletter.